<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="editorial"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Bras Nefrol</journal-id><journal-id journal-id-type="iso-abbrev">J Bras Nefrol</journal-id><journal-id journal-id-type="publisher-id">jbn</journal-id><journal-title-group><journal-title>Jornal Brasileiro de Nefrologia</journal-title></journal-title-group><issn pub-type="ppub">0101-2800</issn><issn pub-type="epub">2175-8239</issn><publisher><publisher-name>Sociedade Brasileira de Nefrologia</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40009792</article-id><article-id pub-id-type="pmc">PMC11864787</article-id>
<article-id pub-id-type="other">00202</article-id><article-id pub-id-type="doi">10.1590/2175-8239-JBN-2025-E001en</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Renal long COVID-19: an ongoing debate requiring robust evidence</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4019-4490</contrib-id><name><surname>Ribeiro</surname><given-names>Heitor S.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role>conceived and designed the editorial</role><role>wrote the first draft</role><role>read and approved the final version</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7644-8579</contrib-id><name><surname>Burdmann</surname><given-names>Emmanuel A.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role>conceived and designed the editorial</role><role>supervised the draft writing and critically reviewed</role><role>read and approved the final version</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9102-0063</contrib-id><name><surname>Yu</surname><given-names>Luis</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role>conceived and designed the editorial</role><role>supervised the draft writing and critically reviewed</role><role>read and approved the final version</role></contrib></contrib-group><aff id="aff1">
<label>1</label>Universidade de S&#x000e3;o Paulo, Faculdade de Medicina, Hospital das Cl&#x000ed;nicas HCFMUSP, Laborat&#x000f3;rio de Investiga&#x000e7;&#x000e3;o M&#x000e9;dica (LIM 12), S&#x000e3;o Paulo, SP, Brazil.</aff><author-notes><corresp id="c001">
<bold>Correspondence to:</bold> Luis Yu. Email: <email>luisyu@usp.br</email>
</corresp><fn fn-type="COI-statement"><p>
<bold>Conflict of Interest</bold> EAB received speaker fees from AstraZeneca and Fresenius unrelated to the submitted work. The other authors declare that they have no competing interests.</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>24</day><month>2</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><season>Jan-Mar</season><year>2025</year></pub-date><volume>47</volume><issue>1</issue><elocation-id>e2025E001</elocation-id><history><date date-type="received"><day>03</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>12</month><year>2024</year></date></history><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><counts><fig-count count="0"/><table-count count="02"/><ref-count count="15"/></counts></article-meta></front><body><p>COVID-19 has a devastating impact on both pulmonary and extrapulmonary systems. The kidneys are frequently affected during the acute phase of COVID-19, with approximately 30% of patients developing acute kidney injury (AKI) and nearly half ultimately dying<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>. For survivors of COVID-19 hospitalization, long-term follow-up and multi-organ screening have been recommended due to the impact on long-term morbidity and mortality and because of the potential burden of long COVID-19 for healthcare systems<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>. Most of the available evidence on long COVID-19 has been focused on cognitive, neurological, psychological, and pulmonary outcomes<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup>. Few prospective cohort studies on renal long COVID-19 have been published, as detailed in <xref rid="T1" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><title>Prospective cohort studies investigating renal long COVID</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Author and year</th><th align="left" valign="top" rowspan="1" colspan="1">Sample (n and characteristics)</th><th align="left" valign="top" rowspan="1" colspan="1">Kidney function markers and time points</th><th align="left" valign="top" rowspan="1" colspan="1">AKI during hospital stay</th><th align="left" valign="top" rowspan="1" colspan="1">Kidney function outcomes at follow-up</th><th align="left" valign="top" rowspan="1" colspan="1">CKD development and/or progression</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Morin et al.<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup> 2021</td><td align="left" valign="top" rowspan="1" colspan="1">478 hospitalized patients</td><td align="left" valign="top" rowspan="1" colspan="1">sCr 4 months</td><td align="left" valign="top" rowspan="1" colspan="1">20% (KDIGO)</td><td align="left" valign="top" rowspan="1" colspan="1">2/177 patients displayed a persistent alteration of kidney function</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Li et al.<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup> 2022</td><td align="left" valign="top" rowspan="1" colspan="1">155 hospitalized patients</td><td align="left" valign="top" rowspan="1" colspan="1">sCr 3, 12 and 24 months<break/>proteinuria 24 months</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">eGFR declined from 3 to 12 months, but not from 12 to 24 months<break/>Proteinuria 7% at 24 months</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gu et al.<sup>
<xref rid="B6" ref-type="bibr">6</xref>
</sup> 2022</td><td align="left" valign="top" rowspan="1" colspan="1">1734 hospitalized patients</td><td align="left" valign="top" rowspan="1" colspan="1">eGFR, proteinuria, and hematuria<break/>6 and 12 months</td><td align="left" valign="top" rowspan="1" colspan="1">6% (KDIGO)</td><td align="left" valign="top" rowspan="1" colspan="1">survivors with AKI had a higher kidney function reduction</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Huang et al.<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup> 2023</td><td align="left" valign="top" rowspan="1" colspan="1">1733 hospitalized patients</td><td align="left" valign="top" rowspan="1" colspan="1">eGFR 6 months</td><td align="left" valign="top" rowspan="1" colspan="1">6% (KDIGO)</td><td align="left" valign="top" rowspan="1" colspan="1">eGFR &#x0003c; 90 mL/min/1.73 m<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>: 479/1378 (35%)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Schmidt-Lauber et al.<sup>
<xref rid="B8" ref-type="bibr">8</xref>
</sup> 2023</td><td align="left" valign="top" rowspan="1" colspan="1">443 non-severe cases</td><td align="left" valign="top" rowspan="1" colspan="1">eGFR, albuminuria, Dickkopf3, hematuria and pyuria 9 months</td><td align="left" valign="top" rowspan="1" colspan="1">non-severe cases<break/>(no AKI)</td><td align="left" valign="top" rowspan="1" colspan="1">mean eGFR mildly lower in post-COVID-19 than non-COVID-19 subjects</td><td align="left" valign="top" rowspan="1" colspan="1">CKD development and albuminuria did not differ between post-COVID-19 and non-COVID-19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mehrotra-Varma et al.<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup> 2024</td><td align="left" valign="top" rowspan="1" colspan="1">748 hospitalized and non-hospitalized patients with type 1 diabetes</td><td align="left" valign="top" rowspan="1" colspan="1">ICD-10 diagnostic codes for CKD</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Compared to non-COVID-19 patients, both hospitalized (11.4% vs. 1.1%) and non-hospitalized (7.7% vs. 1.1%) patients were more likely to develop CKD</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ribeiro et al.<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup> 2024</td><td align="left" valign="top" rowspan="1" colspan="1">655 hospitalized patients</td><td align="left" valign="top" rowspan="1" colspan="1">eGFR, albuminuria, abnormal urine sediment<break/>7 months</td><td align="left" valign="top" rowspan="1" colspan="1">79%: 35% community-acquired and 43% hospital-acquired<break/>(KDIGO)</td><td align="left" valign="top" rowspan="1" colspan="1">16% developed incident low eGFR (&#x0003c;60 mL/min/1.73m<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>)<break/>27% had an eGFR decline of &#x02265;25%<break/>30% had albuminuria and 20% had abnormal urine sediment</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations &#x02013; AKI: Acute Kidney Injury; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; ICD-10: International Classification of Diseases, Tenth Revision; KDIGO: Kidney Disease Improving Global Outcomes; KRT: kidney replacement therapy; MAKE: major adverse kidney events; NR: not reported; sCr: serum creatinine.</p></fn></table-wrap-foot></table-wrap><p>In this issue of the Brazilian Journal of Nephrology, de Andrade et al.<sup>
<xref rid="B11" ref-type="bibr">11</xref>
</sup> prospectively evaluated 360 critically ill COVID-19 patients with AKI during the acute phase of the disease that required a consultation with a nephrologist in a tertiary hospital in the city of Porto Alegre, RS. The authors defined AKI according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria based on serum creatine (sCr). They also evaluated albuminuria and kidney replacement therapy (KRT) need. Recovery of kidney function was defined as independence from KRT or sCr returning to within 50% of baseline, according to the Acute Dialysis Quality Initiative. Overall, they found a very high frequency of severe AKI (KDIGO III - 90.8%), in which 90% required KRT, resulting in an elevated 90-day mortality rate (88%) and only 10% patients recovered renal function. After one year of follow-up, mortality rate was also very high (89%). Among survivors, the estimated glomerular filtration rate (eGFR) after one year was lower than the baseline levels. One methodological issue of this study was the proposed definition of baseline sCr for diagnosing AKI, in which authors looked at the mean creatinine value between 7 and 365 days before hospitalization. However, if not available, the minimum sCr value during hospitalization was adopted. This variation in the definition may bias the internal validity of the AKI diagnosis, especially because the authors do not inform the frequency of patients without baseline sCr. By adopting the minimum sCr value during hospitalization, authors may have overestimated AKI diagnosis. Furthermore, loss of muscle mass, commonly observed in critically ill patients with COVID-19, may have led to a decrease in sCr levels during hospitalization<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup>, which may have resulted in lower sCr value than the actual baseline.</p><p>Another finding that warrants consideration is the extremely high frequency of severe AKI, seldom reported in the literature. Corroborating this finding, 98% of patients needed mechanical ventilation and most of them required KRT (90%). As expected, a nephrology consultation in the critical setting is usually requested for the more severe cases, especially in a pandemic situation, resulting in the selection of severe AKI cases. Nevertheless, it has been reported that nephrology consultation for COVID-19 patients usually results in higher patient survival<sup>
<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>
</sup>. Therefore, there was a clear sample selection bias, which limits generalization to non-severe COVID-19 patients and patients with earlier stages of AKI who are not usually referred to nephrologists.</p><p>The primary endpoints were 90-day mortality, kidney function recovery, and KRT dependence. However, the authors did not report the median survival time. At the end of the 90-day period, only 12% of the patients had survived. The assumption of a 90-day follow-up period may lead to an expectation of a long-term follow-up after hospital discharge, which did not happen for most of the patients. Indeed, mortality at 30 days was 66% and at 60 days 85%, similar to 90-day mortality rate. Therefore, these findings should be carefully interpreted as an in-hospital outcome. In addition, authors included a one-year follow-up for a very small sample of survivors (n = 43; 12%), in which only 25 of the remaining patients (58%) had available eGFR measurement. They have demonstrated that the survivors&#x02019; eGFR was lower than the baseline eGFR (65.9 vs 85.5 mL/min/1.73 m<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>). Although the analysis was secondary and exploratory, caution should be taken in extrapolating the findings to COVID-19 survivors, as the study sample was derived from a biased cohort with very high in-hospital mortality, resulting in long follow-up of a very small sample.</p><p>Although the study is novel in recruiting a sample of patients who required a nephrology consultation, there is already enough data in the literature demonstrating the impact of COVID-19 on kidney-related outcomes during the in-hospital period<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>. At the present time, the discussion should focus on whether long COVID-19 affects the kidneys, rather than how the kidneys are a target organ during the acute phase of infection. As demonstrated in <xref rid="T1" ref-type="table">Table 1</xref>, there are currently few available studies addressing this important issue. Our research group is conducting a prospective cohort study with over 650 survivors of COVID-19 hospitalization in the city of S&#x000e3;o Paulo, SP<sup>
<xref rid="B15" ref-type="bibr">15</xref>
</sup>, with annual follow-up for up to five years after hospital discharge. Preliminary data presented at the XXXII Brazilian Congress of Nephrology and the ASN Kidney Week 2024 showed that 27% of patients experienced a decline in eGFR &#x02265;25%, and 16% were incident for low eGFR (&#x0003c;60 mL/min/1.73 m<sup>2</sup>) after a follow-up of 7&#x000b1;2 months post-hospital discharge<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup>. Interestingly, we found that AKI phenotypes played a different role in the composite outcome of late kidney dysfunction, with community-acquired AKI, but not hospital-acquired AKI, being an independent risk factor.</p><p>The current study by de Andrade et al.<sup>
<xref rid="B11" ref-type="bibr">11</xref>
</sup> sheds light on an area of knowledge that requires attention. Therefore, further research is still needed to better characterize renal long COVID-19 outcomes. The debate remains open and requires robust scientific evidence.</p></body><back><ack><title>Acknowledgments</title><p>EAB receives a research grant (<italic>Bolsa de Produtividade em Pesquisa</italic>, #304743/2017-8) from the National Council for Scientific and Technological Development (CNPq). HSR receives a postdoctoral scholarship from FAPESP (#24/04564-0).</p></ack><ref-list><title>References</title><ref id="B1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Pang</surname><given-names>Q</given-names></name>
<name><surname>Zhou</surname><given-names>T</given-names></name>
<name><surname>Meng</surname><given-names>J</given-names></name>
<name><surname>Dong</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>Z</given-names></name>
<etal/>
</person-group><article-title>Risk factors for acute kidney injury in COVID-19 patients: an updated systematic review and meta-analysis.</article-title><source>Ren Fail.</source><year>2023</year><volume>45</volume><issue>1</issue><fpage>2170809</fpage><pub-id pub-id-type="doi">10.1080/0886022X.2023.2170809</pub-id><pub-id pub-id-type="pmid">37021610</pub-id>
</element-citation></ref><ref id="B2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>C</given-names></name>
<name><surname>Tebbutt</surname><given-names>SJ</given-names></name>
</person-group><article-title>Long COVID: the next public health crisis is already on its way.</article-title><source>Lancet Reg Health Eur.</source><year>2023</year><comment>May</comment><volume>28</volume><fpage>100612</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2023.100612</pub-id><pub-id pub-id-type="pmid">37131860</pub-id>
</element-citation></ref><ref id="B3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandez-de-las-Pe&#x000f1;as</surname><given-names>C</given-names></name>
<name><surname>Notarte</surname><given-names>KI</given-names></name>
<name><surname>Macasaet</surname><given-names>R</given-names></name>
<name><surname>Velasco</surname><given-names>JV</given-names></name>
<name><surname>Catahay</surname><given-names>JA</given-names></name>
<name><surname>Ver</surname><given-names>AT</given-names></name>
<etal/>
</person-group><article-title>Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: a systematic review and meta-analysis.</article-title><source>J Infect.</source><year>2024</year><volume>88</volume><issue>2</issue><fpage>77</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2023.12.004</pub-id><pub-id pub-id-type="pmid">38101521</pub-id>
</element-citation></ref><ref id="B4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Morin</surname><given-names>L</given-names></name>
<name><surname>Savale</surname><given-names>L</given-names></name>
<name><surname>Pham</surname><given-names>T</given-names></name>
<name><surname>Colle</surname><given-names>R</given-names></name>
<name><surname>Figueiredo</surname><given-names>S</given-names></name>
<name><surname>Harrois</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Four-month clinical status of a cohort of patients after hospitalization for COVID-19.</article-title><source>JAMA.</source><year>2021</year><volume>325</volume><issue>15</issue><fpage>1525</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.3331</pub-id><pub-id pub-id-type="pmid">33729425</pub-id>
</element-citation></ref><ref id="B5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>D</given-names></name>
<name><surname>Liao</surname><given-names>X</given-names></name>
<name><surname>Liu</surname><given-names>Z</given-names></name>
<name><surname>Ma</surname><given-names>Z</given-names></name>
<name><surname>Dong</surname><given-names>J</given-names></name>
<name><surname>Zheng</surname><given-names>G</given-names></name>
<etal/>
</person-group><article-title>Healthy outcomes of patients with COVID-19 two years after the infection: a prospective cohort study.</article-title><source>Emerg Microbes Infect.</source><year>2022</year><volume>11</volume><issue>1</issue><fpage>2680</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1080/22221751.2022.2133639</pub-id><pub-id pub-id-type="pmid">36215047</pub-id>
</element-citation></ref><ref id="B6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gu</surname><given-names>X</given-names></name>
<name><surname>Huang</surname><given-names>L</given-names></name>
<name><surname>Cui</surname><given-names>D</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Xu</surname><given-names>J</given-names></name>
<etal/>
</person-group><article-title>Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: A cohort study.</article-title><source>EBioMedicine</source><year>2022</year><volume>76</volume><fpage>103817</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2022.103817</pub-id><pub-id pub-id-type="pmid">35074630</pub-id>
</element-citation></ref><ref id="B7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>C</given-names></name>
<name><surname>Huang</surname><given-names>L</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Ren</surname><given-names>L</given-names></name>
<name><surname>Gu</surname><given-names>X</given-names></name>
<etal/>
</person-group><article-title>6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.</article-title><source>Lancet.</source><year>2023</year><volume>401</volume><issue>10393</issue><fpage>e21</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)00810-3</pub-id><pub-id pub-id-type="pmid">37321233</pub-id>
</element-citation></ref><ref id="B8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmidt-Lauber</surname><given-names>C</given-names></name>
<name><surname>H&#x000e4;nzelmann</surname><given-names>S</given-names></name>
<name><surname>Schunk</surname><given-names>S</given-names></name>
<name><surname>Petersen</surname><given-names>EL</given-names></name>
<name><surname>Alabdo</surname><given-names>A</given-names></name>
<name><surname>Lindenmeyer</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>Kidney outcome after mild to moderate COVID-19.</article-title><source>Nephrol Dial Transplant.</source><year>2023</year><volume>38</volume><issue>9</issue><fpage>2031</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfad008</pub-id><pub-id pub-id-type="pmid">36657383</pub-id>
</element-citation></ref><ref id="B9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehrotra-Varma</surname><given-names>S</given-names></name>
<name><surname>Lu</surname><given-names>JY</given-names></name>
<name><surname>Boparai</surname><given-names>MS</given-names></name>
<name><surname>Henry</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>SH</given-names></name>
<name><surname>Duong</surname><given-names>TQ</given-names></name>
</person-group><article-title>Patients with type 1 diabetes are at elevated risk of developing new hypertension, chronic kidney disease and diabetic ketoacidosis after COVID-19: up to 40 months&#x02019; follow-up.</article-title><source>Diabetes Obes Metab.</source><year>2024</year><volume>26</volume><issue>11</issue><fpage>5368</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1111/dom.15900</pub-id><pub-id pub-id-type="pmid">39223870</pub-id>
</element-citation></ref><ref id="B10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ribeiro</surname><given-names>HS</given-names></name>
<name><surname>Frediani</surname><given-names>MM</given-names></name>
<name><surname>Busatto</surname><given-names>GF</given-names></name>
<name><surname>Carvalho</surname><given-names>CRR</given-names></name>
<name><surname>Mar&#x000e7;al</surname><given-names>LJ</given-names></name>
<name><surname>Santa Catharina</surname><given-names>GP</given-names></name>
<etal/>
</person-group><article-title>Long-term kidney function of COVID-19 survivors: a prospective Cohort study TH-PO1161.</article-title><source>J Am Soc Nephrol.</source><year>2024</year><volume>35</volume><issue>10S</issue><fpage>10.1681/ASN.2024dk11798g</fpage><pub-id pub-id-type="doi">10.1681/ASN.2024dk11798g</pub-id></element-citation></ref><ref id="B11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andrade</surname><given-names>JAM</given-names></name>
<name><surname>Meinerz</surname><given-names>G</given-names></name>
<name><surname>Palma</surname><given-names>R</given-names></name>
<name><surname>Rech</surname><given-names>E</given-names></name>
<name><surname>Dall&#x02019;Agnese</surname><given-names>MAV</given-names></name>
<name><surname>Bundchen</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>Acute kidney injury in critically ill COVID-19 patients in a tertiary hospital: short and long-term kidney and patient outcomes.</article-title><source>Braz J Nephrol.</source><year>2025</year><volume>47</volume><issue>1</issue><fpage>e20240107</fpage><pub-id pub-id-type="doi">10.1590/2175-8239-JBN-2024-0107en</pub-id><pub-id pub-id-type="pmid">39792860</pub-id>
</element-citation></ref><ref id="B12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haines</surname><given-names>RW</given-names></name>
<name><surname>Fowler</surname><given-names>AJ</given-names></name>
<name><surname>Liang</surname><given-names>K</given-names></name>
<name><surname>Pearse</surname><given-names>RM</given-names></name>
<name><surname>Larsson</surname><given-names>AO</given-names></name>
<name><surname>Puthucheary</surname><given-names>Z</given-names></name>
<etal/>
</person-group><article-title>Comparison of cystatin c and creatinine in the assessment of measured kidney function during critical Illness.</article-title><source>Clin J Am Soc Nephrol.</source><year>2023</year><volume>18</volume><issue>8</issue><fpage>997</fpage><lpage>1005</lpage><pub-id pub-id-type="doi">10.2215/CJN.0000000000000203</pub-id><pub-id pub-id-type="pmid">37256861</pub-id>
</element-citation></ref><ref id="B13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>J</given-names></name>
<name><surname>Kim</surname><given-names>SG</given-names></name>
<name><surname>Yun</surname><given-names>D</given-names></name>
<name><surname>Kang</surname><given-names>MW</given-names></name>
<name><surname>Kim</surname><given-names>YC</given-names></name>
<name><surname>Kim</surname><given-names>DK</given-names></name>
<etal/>
</person-group><article-title>Consulting to nephrologist when starting continuous renal replacement therapy for acute kidney injury is associated with a survival benefit.</article-title><source>PLoS One.</source><year>2023</year><volume>18</volume><issue>2</issue><fpage>e0281831</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0281831</pub-id><pub-id pub-id-type="pmid">36791117</pub-id>
</element-citation></ref><ref id="B14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rhee</surname><given-names>H</given-names></name>
<name><surname>Park</surname><given-names>M</given-names></name>
<name><surname>Kim</surname><given-names>IY</given-names></name>
</person-group><article-title>Nephrology consultation improves the clinical outcomes of patients with acute kidney injury.</article-title><source>Kidney Res Clin Pract.</source><year>2023</year><fpage>j.krcp.23.039</fpage><pub-id pub-id-type="doi">10.23876/j.krcp.23.039</pub-id><pub-id pub-id-type="pmid">37798849</pub-id>
</element-citation></ref><ref id="B15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Busatto</surname><given-names>GF</given-names></name>
<name><surname>de Ara&#x000fa;jo</surname><given-names>AL</given-names></name>
<name><surname>Duarte</surname><given-names>AJDS</given-names></name>
<name><surname>Levin</surname><given-names>AS</given-names></name>
<name><surname>Guedes</surname><given-names>BF</given-names></name>
<name><surname>Kallas</surname><given-names>EG</given-names></name>
<etal/>
</person-group><article-title>Post-acute sequelae of SARS-CoV-2 infection (PASC): a protocol for a multidisciplinary prospective observational evaluation of a cohort of patients surviving hospitalisation in Sao Paulo, Brazil.</article-title><source>BMJ Open.</source><year>2021</year><volume>11</volume><issue>6</issue><fpage>e051706</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2021-051706</pub-id><pub-id pub-id-type="pmid">34193506</pub-id>
</element-citation></ref></ref-list></back><sub-article article-type="translation" id="s1" xml:lang="pt"><front-stub><article-id pub-id-type="doi">10.1590/2175-8239-JBN-2025-E001pt</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>COVID-19 longa renal: um debate em andamento que requer evid&#x000ea;ncias robustas</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4019-4490</contrib-id><name><surname>Ribeiro</surname><given-names>Heitor S.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>1</sup>
</xref><role>conceberam e desenharam o editorial</role><role>redigiu o primeiro esbo&#x000e7;o</role><role>leram e aprovaram a vers&#x000e3;o final</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7644-8579</contrib-id><name><surname>Burdmann</surname><given-names>Emmanuel A.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>1</sup>
</xref><role>conceberam e desenharam o editorial</role><role>supervisionaram a reda&#x000e7;&#x000e3;o do texto preliminar e o revisaram criticamente</role><role>leram e aprovaram a vers&#x000e3;o final</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9102-0063</contrib-id><name><surname>Yu</surname><given-names>Luis</given-names></name><xref rid="aff2" ref-type="aff">
<sup>1</sup>
</xref><role>conceberam e desenharam o editorial</role><role>supervisionaram a reda&#x000e7;&#x000e3;o do texto preliminar e o revisaram criticamente</role><role>leram e aprovaram a vers&#x000e3;o final</role></contrib></contrib-group><aff id="aff2">
<label>1</label>Universidade de S&#x000e3;o Paulo, Faculdade de Medicina, Hospital das Cl&#x000ed;nicas HCFMUSP, Laborat&#x000f3;rio de Investiga&#x000e7;&#x000e3;o M&#x000e9;dica (LIM 12), S&#x000e3;o Paulo, SP, Brasil.</aff><author-notes><corresp id="c002">
<bold>Correspond&#x000ea;ncia para:</bold> Luis Yu. Email: <email>luisyu@usp.br</email>
</corresp><fn fn-type="COI-statement"><p>
<bold>Conflito de Interesse</bold> EAB recebeu honor&#x000e1;rios de palestrante da AstraZeneca e Fresenius n&#x000e3;o relacionados ao trabalho enviado. Os outros autores declaram n&#x000e3;o ter interesses conflitantes.</p></fn></author-notes></front-stub><body><p>A COVID-19 tem um impacto devastador nos sistemas pulmonar e extrapulmonar. Os rins s&#x000e3;o frequentemente afetados durante a fase aguda da COVID-19, com aproximadamente 30% dos pacientes desenvolvendo inj&#x000fa;ria renal aguda (IRA) e quase metade evoluindo para &#x000f3;bito<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>. Para os sobreviventes de hospitaliza&#x000e7;&#x000f5;es por COVID-19, recomenda-se o acompanhamento de longo prazo e a triagem de m&#x000fa;ltiplos &#x000f3;rg&#x000e3;os devido ao impacto na morbidade e mortalidade a longo prazo, bem como ao poss&#x000ed;vel &#x000f4;nus da COVID-19 longa para os sistemas de sa&#x000fa;de<sup>
<xref rid="B2" ref-type="bibr">2</xref>
</sup>. A maior parte das evid&#x000ea;ncias dispon&#x000ed;veis sobre a COVID-19 longa tem se concentrado em desfechos cognitivos, neurol&#x000f3;gicos, psicol&#x000f3;gicos e pulmonares<sup>
<xref rid="B3" ref-type="bibr">3</xref>
</sup>. Poucos estudos de coorte prospectivos sobre a COVID-19 longa renal foram publicados, conforme detalhado na <xref rid="T2" ref-type="table">Tabela 1</xref>.</p><table-wrap position="float" id="T2"><label>Tabela 1</label><caption><title>Estudos de coorte prospectivos que investigam a COVID-19 longa renal</title></caption><table frame="hsides" rules="groups" cellpadding="5" cellspacing="5"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Autor e ano</th><th align="left" valign="top" rowspan="1" colspan="1">Amostra (n e caracter&#x000ed;sticas)</th><th align="left" valign="top" rowspan="1" colspan="1">Marcadores de fun&#x000e7;&#x000e3;o renal e pontos temporais</th><th align="left" valign="top" rowspan="1" colspan="1">IRA durante a hospitaliza&#x000e7;&#x000e3;o</th><th align="left" valign="top" rowspan="1" colspan="1">Desfechos da fun&#x000e7;&#x000e3;o renal no acompanhamento</th><th align="left" valign="top" rowspan="1" colspan="1">Desenvolvimento e/ou progress&#x000e3;o da DRC</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Morin et al.<sup>
<xref rid="B4" ref-type="bibr">4</xref>
</sup> 2021</td><td align="left" valign="top" rowspan="1" colspan="1">478 pacientes hospitalizados</td><td align="left" valign="top" rowspan="1" colspan="1">CrS 4 meses</td><td align="left" valign="top" rowspan="1" colspan="1">20% (KDIGO)</td><td align="left" valign="top" rowspan="1" colspan="1">2/177 pacientes apresentaram altera&#x000e7;&#x000e3;o persistente da fun&#x000e7;&#x000e3;o renal</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Li et al.<sup>
<xref rid="B5" ref-type="bibr">5</xref>
</sup> 2022</td><td align="left" valign="top" rowspan="1" colspan="1">155 pacientes hospitalizados</td><td align="left" valign="top" rowspan="1" colspan="1">CrS<break/>3, 12 e 24 meses<break/>protein&#x000fa;ria 24 meses</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">A TFGe diminuiu entre 3 a 12 meses, mas n&#x000e3;o entre 12 a 24 meses<break/>Protein&#x000fa;ria 7% em 24 meses</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gu et al.<sup>
<xref rid="B6" ref-type="bibr">6</xref>
</sup> 2022</td><td align="left" valign="top" rowspan="1" colspan="1">1734 pacientes hospitalizados</td><td align="left" valign="top" rowspan="1" colspan="1">TFGe, protein&#x000fa;ria e hemat&#x000fa;ria<break/>6 e 12 meses</td><td align="left" valign="top" rowspan="1" colspan="1">6% (KDIGO)</td><td align="left" valign="top" rowspan="1" colspan="1">sobreviventes com IRA apresentaram maior redu&#x000e7;&#x000e3;o da fun&#x000e7;&#x000e3;o renal</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Huang et al.<sup>
<xref rid="B7" ref-type="bibr">7</xref>
</sup> 2023</td><td align="left" valign="top" rowspan="1" colspan="1">1733 pacientes hospitalizados</td><td align="left" valign="top" rowspan="1" colspan="1">TFGe 6 meses</td><td align="left" valign="top" rowspan="1" colspan="1">6% (KDIGO)</td><td align="left" valign="top" rowspan="1" colspan="1">TFGe &#x0003c; 90 mL/min/1,73 m<sup>2</sup>: 479/1378 (35%)</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Schmidt-Lauber et al.<sup>
<xref rid="B8" ref-type="bibr">8</xref>
</sup> 2023</td><td align="left" valign="top" rowspan="1" colspan="1">443 casos n&#x000e3;o graves</td><td align="left" valign="top" rowspan="1" colspan="1">TFGe, albumin&#x000fa;ria, Dickkopf3, hemat&#x000fa;ria e pi&#x000fa;ria<break/>9 meses</td><td align="left" valign="top" rowspan="1" colspan="1">casos n&#x000e3;o graves (sem IRA)</td><td align="left" valign="top" rowspan="1" colspan="1">TFGe m&#x000e9;dia levemente menor em indiv&#x000ed;duos p&#x000f3;s-COVID-19 do que em indiv&#x000ed;duos sem COVID-19</td><td align="left" valign="top" rowspan="1" colspan="1">Desenvolvimento de DRC e albumin&#x000fa;ria n&#x000e3;o diferiram entre p&#x000f3;s-COVID-19 e n&#x000e3;o COVID-19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mehrotra-Varma et al.<sup>
<xref rid="B9" ref-type="bibr">9</xref>
</sup> 2024</td><td align="left" valign="top" rowspan="1" colspan="1">748 pacientes hospitalizados e n&#x000e3;o hospitalizados com diabetes tipo 1</td><td align="left" valign="top" rowspan="1" colspan="1">C&#x000f3;digos de diagn&#x000f3;stico CID-10 para DRC</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">NR</td><td align="left" valign="top" rowspan="1" colspan="1">Comparados aos pacientes sem COVID-19, pacientes hospitalizados (11,4% vs. 1,1%) e n&#x000e3;o hospitalizados (7,7% vs. 1,1%) apresentaram maior probabilidade de desenvolver DRC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ribeiro et al.<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup> 2024</td><td align="left" valign="top" rowspan="1" colspan="1">655 pacientes hospitalizados</td><td align="left" valign="top" rowspan="1" colspan="1">TFGe, albumin&#x000fa;ria, sedimento urin&#x000e1;rio anormal<break/>7 meses</td><td align="left" valign="top" rowspan="1" colspan="1">79%: 35% adquiridos na comunidade e 43% adquiridos no hospital<break/>(KDIGO)</td><td align="left" valign="top" rowspan="1" colspan="1">16% desenvolveram baixa TFGe incidente (&#x0003c;60 mL/min/1,73m<sup>2</sup>)<break/>27% apresentaram um decl&#x000ed;nio da TFGe de &#x02265;25%<break/>30% apresentaram albumin&#x000fa;ria e 20% apresentaram sedimento urin&#x000e1;rio anormal</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Abrevia&#x000e7;&#x000f5;es &#x02013; IRA: inj&#x000fa;ria renal aguda; DRC: doen&#x000e7;a renal cr&#x000f4;nica; TFGe: taxa de filtra&#x000e7;&#x000e3;o glomerular estimada; CID-10: Classifica&#x000e7;&#x000e3;o Internacional de Doen&#x000e7;as, D&#x000e9;cima Revis&#x000e3;o; KDIGO: Kidney Disease Improving Global Outcomes; TRS: terapia renal substitutiva; MAKE: eventos renais adversos maiores; NR: n&#x000e3;o relatado; CrS: creatinina s&#x000e9;rica.</p></fn></table-wrap-foot></table-wrap><p>Nesta edi&#x000e7;&#x000e3;o do Jornal Brasileiro de Nefrologia, de Andrade et al.<sup>
<xref rid="B11" ref-type="bibr">11</xref>
</sup> avaliaram prospectivamente 360 pacientes graves com COVID-19 e IRA, durante a fase aguda da doen&#x000e7;a, que necessitaram de consulta com um nefrologista em um hospital terci&#x000e1;rio na cidade de Porto Alegre, RS. Os autores definiram a IRA de acordo com os crit&#x000e9;rios do <italic>Kidney Disease: Improving Global Outcomes</italic> (KDIGO), com base na creatinina s&#x000e9;rica (CrS). Eles tamb&#x000e9;m avaliaram a albumin&#x000fa;ria e a necessidade de terapia renal substitutiva (TRS). A recupera&#x000e7;&#x000e3;o da fun&#x000e7;&#x000e3;o renal foi definida como a independ&#x000ea;ncia da TRS ou o retorno da CrS a um valor dentro de 50% do basal, de acordo com a <italic>Acute Dialysis Quality Initiative</italic>. De modo geral, os autores constataram uma frequ&#x000ea;ncia muito alta de IRA grave (KDIGO III - 90,8%), na qual 90% necessitaram de TRS, resultando em uma elevada taxa de mortalidade em 90 dias (88%, com apenas 10% dos pacientes recuperando a fun&#x000e7;&#x000e3;o renal). Ap&#x000f3;s um ano de acompanhamento, a taxa de mortalidade tamb&#x000e9;m foi bastante elevada (89%). Entre os sobreviventes, a taxa de filtra&#x000e7;&#x000e3;o glomerular estimada (TFGe) ap&#x000f3;s um ano foi inferior aos n&#x000ed;veis basais. Uma quest&#x000e3;o metodol&#x000f3;gica deste estudo foi a defini&#x000e7;&#x000e3;o proposta do valor basal de CrS para o diagn&#x000f3;stico de IRA, na qual os autores analisaram o valor m&#x000e9;dio de creatinina entre 7 e 365 dias antes da hospitaliza&#x000e7;&#x000e3;o. Entretanto, caso essa informa&#x000e7;&#x000e3;o n&#x000e3;o estivesse dispon&#x000ed;vel, foi adotado o valor m&#x000ed;nimo de CrS durante a hospitaliza&#x000e7;&#x000e3;o. Essa varia&#x000e7;&#x000e3;o na defini&#x000e7;&#x000e3;o pode enviesar a validade interna do diagn&#x000f3;stico de IRA, especialmente porque os autores n&#x000e3;o informam a frequ&#x000ea;ncia de pacientes sem valores basais de CrS. Ao adotar o valor m&#x000ed;nimo de CrS durante a hospitaliza&#x000e7;&#x000e3;o, os autores podem ter superestimado o diagn&#x000f3;stico de IRA. Al&#x000e9;m disso, a perda de massa muscular, comumente observada em pacientes cr&#x000ed;ticos com COVID-19, pode ter levado a uma redu&#x000e7;&#x000e3;o nos n&#x000ed;veis de CrS durante a hospitaliza&#x000e7;&#x000e3;o<sup>
<xref rid="B12" ref-type="bibr">12</xref>
</sup>, o que pode ter resultado em um valor de CrS inferior ao valor basal real.</p><p>Outro achado que merece considera&#x000e7;&#x000e3;o &#x000e9; a frequ&#x000ea;ncia extremamente elevada de IRA grave, raramente reportada na literatura. Corroborando esse achado, 98% dos pacientes necessitaram de ventila&#x000e7;&#x000e3;o mec&#x000e2;nica e a maioria deles precisou de TRS (90%). Conforme esperado, uma consulta de nefrologia no ambiente cr&#x000ed;tico geralmente &#x000e9; solicitada para os casos mais graves, especialmente em uma situa&#x000e7;&#x000e3;o de pandemia, resultando na sele&#x000e7;&#x000e3;o de casos graves de IRA. N&#x000e3;o obstante, foi relatado que a consulta de nefrologia para indiv&#x000ed;duos com COVID-19 geralmente resulta em maior sobrevida do paciente<sup>
<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>
</sup>. Portanto, houve um claro vi&#x000e9;s de sele&#x000e7;&#x000e3;o da amostra, o qual limita a generaliza&#x000e7;&#x000e3;o para pacientes com COVID-19 n&#x000e3;o grave e pacientes com est&#x000e1;gios iniciais de IRA que geralmente n&#x000e3;o s&#x000e3;o encaminhados aos nefrologistas.</p><p>Os desfechos prim&#x000e1;rios foram mortalidade em 90 dias, recupera&#x000e7;&#x000e3;o da fun&#x000e7;&#x000e3;o renal e depend&#x000ea;ncia de TRS. No entanto, os autores n&#x000e3;o relataram o tempo m&#x000e9;dio de sobrevida. Ao final do per&#x000ed;odo de 90 dias, apenas 12% dos pacientes haviam sobrevivido. A suposi&#x000e7;&#x000e3;o de um per&#x000ed;odo de acompanhamento de 90 dias pode levar &#x000e0; expectativa de um acompanhamento de longo prazo ap&#x000f3;s a alta hospitalar, o que n&#x000e3;o ocorreu para a maioria dos pacientes. De fato, a mortalidade aos 30 dias foi de 66% e aos 60 dias foi de 85%, semelhante &#x000e0; taxa de mortalidade aos 90 dias. Portanto, esses achados devem ser cuidadosamente interpretados como um desfecho intra-hospitalar. Al&#x000e9;m disso, os autores inclu&#x000ed;ram um acompanhamento de um ano para uma amostra muito pequena de sobreviventes (n = 43; 12%), na qual somente 25 dos pacientes remanescentes (58%) tinham medi&#x000e7;&#x000f5;es de TFGe dispon&#x000ed;veis. Eles demonstraram que a TFGe dos sobreviventes foi inferior &#x000e0; TFGe basal (65,9 <italic>vs.</italic> 85,5 mL/min/1,73 m<sup>2</sup>). Embora a an&#x000e1;lise tenha sido secund&#x000e1;ria e explorat&#x000f3;ria, deve-se ter cautela ao extrapolar os achados para os sobreviventes da COVID-19, uma vez que a amostra do estudo foi derivada de uma coorte tendenciosa, com mortalidade hospitalar muito elevada, resultando em um longo acompanhamento de uma amostra muito pequena.</p><p>Embora o estudo seja inovador ao recrutar uma amostra de pacientes que necessitaram de consulta nefrol&#x000f3;gica, j&#x000e1; existem dados suficientes na literatura demonstrando o impacto da COVID-19 nos desfechos renais durante o per&#x000ed;odo hospitalar<sup>
<xref rid="B1" ref-type="bibr">1</xref>
</sup>. No momento, a discuss&#x000e3;o deve concentrar-se em determinar se a COVID-19 longa afeta os rins, em vez de como os rins s&#x000e3;o um &#x000f3;rg&#x000e3;o-alvo durante a fase aguda da infec&#x000e7;&#x000e3;o. Conforme demonstrado na <xref rid="T2" ref-type="table">Tabela 1</xref>, atualmente existem poucos estudos dispon&#x000ed;veis abordando essa importante quest&#x000e3;o. Nosso grupo de pesquisa est&#x000e1; realizando um estudo de coorte prospectivo com mais de 650 sobreviventes da hospitaliza&#x000e7;&#x000e3;o por COVID-19 na cidade de S&#x000e3;o Paulo, SP<sup>
<xref rid="B15" ref-type="bibr">15</xref>
</sup>, com acompanhamento anual por at&#x000e9; cinco anos ap&#x000f3;s a alta hospitalar. Dados preliminares apresentados no XXXII Congresso Brasileiro de Nefrologia e na <italic>ASN Kidney Week 2024</italic> mostraram que 27% dos pacientes apresentaram um decl&#x000ed;nio na TFGe &#x02265;25%, e 16% tiveram incid&#x000ea;ncia de TFGe baixa (&#x0003c;60 mL/min/1,73 m<sup>2</sup>) ap&#x000f3;s um acompanhamento de 7&#x000b1;2 meses p&#x000f3;s-alta hospitalar<sup>
<xref rid="B10" ref-type="bibr">10</xref>
</sup>. Curiosamente, constatamos que os fen&#x000f3;tipos de IRA desempenharam um papel diferente no desfecho composto da disfun&#x000e7;&#x000e3;o renal tardia, sendo a IRA adquirida na comunidade, e n&#x000e3;o a IRA adquirida no hospital, um fator de risco independente.</p><p>O estudo atual por de Andrade et al.<sup>
<xref rid="B11" ref-type="bibr">11</xref>
</sup> lan&#x000e7;a luz sobre uma &#x000e1;rea de conhecimento que requer aten&#x000e7;&#x000e3;o. Portanto, ainda s&#x000e3;o necess&#x000e1;rias mais pesquisas para melhor caracterizar os desfechos da COVID-19 longa renal. O debate permanece aberto e demanda evid&#x000ea;ncias cient&#x000ed;ficas robustas.</p></body><back><ack><title>Agradecimentos</title><p>EAB recebe bolsa de pesquisa (Bolsa de Produtividade em Pesquisa, n&#x000ba; 304743/2017-8) do Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico (CNPq). HSR recebe bolsa de p&#x000f3;s-doutorado da FAPESP (n&#x000ba; 24/04564-0).</p></ack></back></sub-article></article>